Dysfunctional disorders of the biliary tract in the Rome V criteria consensus. Therapeutic capabilities of trimebutine
Trukhan D.I., Rozhkova M.Yu., Akimova M.A., Goloshubina V.V.
Dysfunctional biliary tract disorders represent a complex of clinical symptoms resulting from motor-tonic dysfunction of the gallbladder, bile ducts, and sphincters. Primary biliary tract dysfunction accounts for approximately 4%. The incidence of secondary biliary tract dysfunction is significantly higher and can reach 100% in cases of organic diseases of the gallbladder and biliary tract. This article discusses clinical and diagnostic criteria for biliary tract dysfunction in accordance with Rome V criteria (2026). Changes in section E - “Disorders of the gallbladder and sphincter of Oddi” of the new edition of the consensus “Rome V criteria” (2026) are aimed at a clearer definition of biliary pain, improving the diagnostic criteria for dysfunctional disorders of the gallbladder and disorders of the sphincter of Oddi.
When considering the treatment of functional biliary tract disorders in the Rome IV and Rome V consensus criteria, special attention is given to trimebutine. We searched the Pubmed, Scopus, and Elibrary.ru databases for articles published before May 1, 2026, that examined the properties and effects of trimebutine, with a focus on its effects on the hepatobiliary system. The sources identified suggest that trimebutine (Trimedat®) is a multitarget drug, as it promotes normal motility, reduces visceral hypersensitivity, and exhibits anti-inflammatory and neuromodulatory effects, which enhances the effectiveness of treating functional biliary tract disorders.
The presented results of studies of the efficacy and safety of trimebutine (Trimedat®) in patients with dysfunction of the gallbladder and sphincter of Oddi, which demonstrated a significant improvement in clinical symptoms and laboratory parameters, indicate the effectiveness of the use of trimebutine in the standard therapy of biliary tract dysfunctions.
For citations: Trukhan D.I., Rozhkova M.Yu., Akimova M.A., Goloshubina V.V. Dysfunctional disorders of the biliary tract in the Rome V criteria consensus. Therapeutic capabilities of trimebutine. Pharmateca. 2026;33(4):40-50. (In Russ.). DOI: https://dx.doi.org/10.18565/pharmateca.2026.4.40-50
Contribution of authors: Concept of the article – Trukhan D.I. Text development – Trukhan D.I. Literature review – Trukhan D.I., Rozhkova M.Yu., Akimova M.A., Goloshubina V.V. Material analysis – Trukhan D.I., Rozhkova M.Yu., Akimova M.A., Goloshubina V.V. Editing – Trukhan D.I., Rozhkova M.Yu. Approval of the final version of the article – Trukhan D.I., Rozhkova M.Yu.
Conflicts of interest: The authors confirm that they have no conflicts of interest to declare.
Funding: The study was conducted without any sponsorship.
Keywords
biliary tract dysfunction
gallbladder
sphincter of Oddi
Rome IV criteria
Rome V criteria
diagnosis
treatment
trimebutine
About the Authors
Dmitry I. Trukhan, Dr. Sci. (Med.), Associate Professor, Professor of the Chair of Polyclinic Therapy and Internal Diseases, Omsk State Medical University, Omsk, Russia; dmitry_trukhan@mail.ru, ORCID: https://dx.doi.org/0000-0002-1597-1876 (corresponding author)Maria Yu. Rozhkova, Cand. Sci. (Med.),Associate Professor of the Department of Polyclinic Therapy and Internal Diseases, Omsk State Medical University, Omsk, Russia; marroj@mail.ru ORCID: https://dx.doi.org/0000-0002-7695-149X
Marina A. Akimova, Cand. Sci. (Med.), Assistant of the Department of Polyclinic Therapy and Internal Diseases, Omsk State Medical University, Omsk, Russia; akim7marin@mail.ru
Victoria V. Goloshubina, Cand. Sci. (Med.), Associate Professor of the Department of Polyclinic Therapy and Internal Diseases, Omsk State Medical University, Omsk, Russia; vikulka03@mail.ru ORCID: https://dx.doi.org/0000-0003-1481-8842
Similar Articles
